Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

被引:5
|
作者
Lawson, Alexander [1 ]
Kamarajah, Sivesh K. [2 ]
Parente, Alessandro [2 ]
Pufal, Kamil [1 ]
Sundareyan, Ramanivas [3 ]
Pawlik, Timothy M. [4 ]
Ma, Yuk Ting [5 ]
Shah, Tahir [6 ]
Kharkhanis, Salil [3 ]
Dasari, Bobby V. M. [2 ,7 ]
机构
[1] Univ Birmingham, Birmingham Med Sch, Birmingham B15 2TT, England
[2] Queen Elizabeth Hosp, Dept HPB & Liver Transplantat, Birmingham B15 2TH, England
[3] Queen Elizabeth Hosp, Dept Radiol, Birmingham B15 2TH, England
[4] Ohio State Univ, Wexner Med Ctr, Dept Surg, Columbus, OH 43210 USA
[5] Queen Elizabeth Hosp, Dept Oncol, Birmingham B15 2TH, England
[6] Queen Elizabeth Hosp, Liver Unit, Birmingham B15 2TH, England
[7] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham B15 2TT, England
关键词
hepatocellular carcinoma; transarterial embolisation; transarterial chemoembolisation; TRANSCATHETER ARTERIAL EMBOLIZATION; DRUG-ELUTING BEADS; CONVENTIONAL CHEMOEMBOLIZATION; BLAND EMBOLIZATION; TRIAL;
D O I
10.3390/cancers15123166
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Non-surgical management of hepatocellular carcinoma (HCC) is used for selected patients. Of these management options, transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) are the two main locoregional treatment options. There was no difference in OS among patients treated with TACE/TAE, single versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has a comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs, which are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future. Although hepatocellular carcinoma is increasingly common, debate exists surrounding the management of patients with unresectable disease comparing transarterial embolisation (TAE) or transarterial chemoembolisation (TACE). This study aimed to compare the outcomes of patients receiving TAE and TACE. A systematic review was performed using PubMed, Medline, Embase, and Cochrane databases to identify randomised controlled trials (RCTs) until August 2021. The primary outcome was overall survival (OS) and the secondary outcomes were progression-free survival (PFS) and adverse events. Five studies with 609 patients were included in the analysis. There was no statistically significant difference in the OS (p = 0.36) and PFS (p = 0.81). There was no difference in OS among patients treated with a single TACE/TAE versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Results of transarterial chemoembolisation (TACE) therapy for hepatocellular carcinoma (HCC) in a general hospital in Singapore
    Kwek, Andrew
    Teo, Eng Kiong
    Tan, Jessica
    Fock, Kwong Ming
    Chua, Tju Siang
    Poh, Choo Hean
    Gan, Lian Hoe
    Tan, Poh Seng
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A179 - A179
  • [42] Long-term survival and postoperative complications of pre-liver transplantation transarterial chemoembolisation in hepatocellular carcinoma: A systematic review and meta-analysis
    Butcher, Daniel A.
    Brandis, Kelli J.
    Wang, Haolu
    Spannenburg, Liam
    Bridle, Kim R.
    Crawford, Darrell HG.
    Liang, Xiaowen
    EJSO, 2022, 48 (03): : 621 - 631
  • [43] Radiomics as a tool for prognostic prediction in transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis
    Deng, Kaige
    Chen, Tong
    Leng, Zijian
    Yang, Fan
    Lu, Tao
    Cao, Jingying
    Pan, Weixuan
    Zheng, Yongchang
    RADIOLOGIA MEDICA, 2024, 129 (08): : 1099 - 1117
  • [44] Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis
    Silva, Jack P.
    Berger, Nicholas G.
    Tsai, Susan
    Christians, Kathleen K.
    Clarke, Callisia N.
    Mogal, Harveshp
    White, Sarah
    Rilling, William
    Gamblin, T. Clark
    HPB, 2017, 19 (08) : 659 - 666
  • [45] Efficacy of Transarterial Chemoembolization Combined With Camrelizumab in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Tashrifwala, Fatema Ali Asgar
    Karmani, Vikash Kumar
    Haider, Ihtisham
    Syeda, Amna Zubia
    Noorani, Amber
    Mustafa, Muhammad Saqlain
    Dave, Tirth
    Hafeez, Hassan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [46] Comparison of combined transarterial chemoembolization and ablations in patients with hepatocellular carcinoma: a systematic review and meta-analysis
    Keshavarz, Pedram
    Raman, Steven S.
    ABDOMINAL RADIOLOGY, 2022, 47 (03) : 1009 - 1023
  • [47] Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Li, Lin
    Zhao, Wenzhuo
    Wang, Mengmeng
    Hu, Jie
    Wang, Enxin
    Zhao, Yan
    Liu, Lei
    BMC GASTROENTEROLOGY, 2018, 18
  • [48] Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Lin Li
    Wenzhuo Zhao
    Mengmeng Wang
    Jie Hu
    Enxin Wang
    Yan Zhao
    Lei Liu
    BMC Gastroenterology, 18
  • [49] Comparison of combined transarterial chemoembolization and ablations in patients with hepatocellular carcinoma: a systematic review and meta-analysis
    Pedram Keshavarz
    Steven S. Raman
    Abdominal Radiology, 2022, 47 : 1009 - 1023
  • [50] Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis
    Zhang, Leida
    Hu, Peng
    Chen, Xi
    Bie, Ping
    PLOS ONE, 2014, 9 (06):